Rebecca Wagers, CPESN® NET Managing Network Facilitator, says the Emergent ACO Special Purpose Partnership has expanded to seven states and that CPESN pharmacies have submiitted more than 50,000 eCare plans. And that's just the start.

Eric Hughes, CPESN® Arkansas Managing Network Facilitator, describes one of three new RxE2 clinical trial recruitment recruitment opportunities for 2023. In this multi-state recruitment, pharamcies in several networks review prescribing records to identify patients with treatment-resistent depression. Some patients with a specific gene marker may participate in an investigational drug study. It's a payable opportunity for patients, and creates network revenue as well.

Community pharmacies educating patients - especially in underserved communities - about health conditions and access to clinical trials is the focus of a partnership between CPESN® USA and Inside Edge Consulting Group.

Cold calls to the South Dakota Department of Health five years ago opened the way for a successful hypertension management program. The small network in a rural state has tripled in size and delivered cardiovascular risk reduction programs to more than 150 patients.

CPESN® Hawaii credits a unified marketing front, persistence, and leveraging COVID-19 opportunities for that network's steady growth and payer contracts.

CPESN® USA PPP Regional Lead Laura Rhodes describes how pharmacies in CPESN® Virginia and CPESN® Florida collectively engaged dually eligible patients in a quick turn program to obtain blood pressure readings and help the MCO close care gaps. Looking forward, Rhodes says with an earlier start in the year, CPESN community pharmacy efforts can deliver greater impact for MCO payers.

Grant-funded Nicotene Replacement Therapy program helped CPESN® California pharmacies refine workflows and create patient awareness of health services under expanded Medi-Cal coverage. Pharmacy Support Staff were critical to program success.

Breah Schibi of Bowen Pharmacy in Parsons, Kansas describes her positive experience with offering self-administered early cognitive testing to 65+ pharmacy patients. Bowen is one of 29 CPESN pharmacies selected for the program in partership with Avant Institute and funded by the global Davos Alzheimer's Initiative.

G&M Pharmacy in Oxford, MS is one of five CPESN community pharmacies to complete a multi-state pilot program with RxE2 where deidentified patient gender, race, ethnic data was collected and reported. The program demonstrates how the community pharmacy relationship with patients can help expand access to clinical trials for underrepresented ethnic and racial populations.

RxSelect CPESN® the Oklahoma local network provides comprehensive and targeted medication reviews for Medicaid patients at a high risk for return hospitalization or emergency visits. The result = lower total cost of care.